Filing Details

Accession Number:
0001104659-20-048399
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-04-20 06:07:32
Reporting Period:
2020-04-15
Accepted Time:
2020-04-20 06:07:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1264587 Stemline Therapeutics Inc STML Pharmaceutical Preparations (2834) 450522567
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1554767 Ivan Bergstein C/O Stemline Therapeutics, Inc.
750 Lexington Avenue, Eleventh Floor
New York NY 10022
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-04-15 53,618 $4.88 2,804,336 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. In connection with the vesting of 94,916 shares on April 14, 2020, a total of 53,618 shares were sold by the Company on April 15, 2020 in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies.
  2. Reflects the weighted average sale price. The range of prices for the shares sold on April 15, 2020 was $4.79 to $5.06. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.
  3. Of the shares listed, 762,035 shares are restricted stock.